Recent developments in multiple sclerosis therapeutics

BMC Medicine

Volumn 7, Issue , 2009, Pages

  Spain, Rebecca I ^a   Cameron, Michelle H ^a   Bourdette, Dennis ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; ALEMTUZUMAB; ARTEMIN; BETA INTERFERON; BETA1A INTERFERON; BG 00012; CLADRIBINE; CORTICOSTEROID; DACLIZUMAB; ESTRIOL; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERFERON BETA SERINE; LAMOTRIGINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; NERVE GROWTH FACTOR; NEURTURIN; PERSEPHIN; PLACEBO; PROGESTERONE; RILUZOLE; RITUXIMAB; SOMATOMEDIN; TERIFLUNOMIDE; THIOCTIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PEPTIDE;

ANEMIA; CELL MIGRATION; CELL PROLIFERATION; CHICKENPOX; CLINICAL TRIAL; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; GRAVES DISEASE; GUILLAIN BARRE SYNDROME; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; HUMAN; INFECTION; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; NEUROPROTECTION; NEUTROPENIA; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PREGNANCY; PROGESTERONE BLOOD LEVEL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SHORT SURVEY; SKIN CANCER; T LYMPHOCYTE; THROMBOCYTOPENIC PURPURA; THROMBOSIS; TREATMENT RESPONSE; ARTICLE;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 73149094510     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-7-74     Document Type: Short Survey

References (53)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517. 10.1016/S0140-6736(08)61620-7, 18970977.
2. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006, (354):942-955. 10.1056/NEJMra052130, 16510748.
3. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129:606-616. 10.1093/brain/awl007, 16415308.
4. Kezele IB, Arnold DL, Collins DL. Atrophy in white matter fiber tracts in multiple sclerosis is not dependent on tract length or local white matter lesions. Mult Scler 2008, 14:779-785. 10.1177/1352458507088106, 18611990.
5. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987, 50:511-516. 10.1136/jnnp.50.5.511, 1031960, 3295122.
6. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001, 57:1239-1247.
7. Beck RW. The Optic Neuritis Treatment Trial. Arch Ophthalmol 1988, 106:1051-1053.
8. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661. The IFNB Multiple Sclerosis Study Group.
9. Goodkin D. Interferon beta-1b. Lancet 1994, 344:1057-1060. 10.1016/S0140-6736(94)91713-2, 7934448.
10. Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007, 29:2031-2048. 10.1016/j.clinthera.2007.09.025, 18035202.
11. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992, 242:96-102. 10.1007/BF02191555, 1486115.
12. Noseworthy JH, Hopkins MB, Vandervoort MK, Karlik SJ, Lee DH, Penman M, Rice GP, Grinwich KD, Cauvier H, Harris BJ. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993, 43:1401-1406.
13. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraud O. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997, 62:112-118. 10.1136/jnnp.62.2.112, 486720, 9048709.
14. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW, . Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003, 61:1332-1338.
15. Ghalie RG, Mauch E, Edan G, Hartung HP, Gonsette RE, Eisenmann S, Le Page E, Butine MD, De Goodkin DE. A study of therapy-related acute leukemia after mitoxantrone therapy for multiple sclerosis.[see comment]. Mult Scler 2002, (8):441-445. 10.1191/1352458502ms836oa, 12356214.
16. Voltz R, Starck M, Zingler V, Strupp M, Kolb HJ. Mitoxantrone therapy in multiple sclerosis and acute leukemia: a case report out of 644 treated patients. Mult Scler 2004, 10:472-474. 10.1191/1352458504ms1047cr, 15327049.
17. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007, (356):2622-2629. 10.1056/NEJMct071462, 17582072.
18. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, . AFFIRM Investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910. 10.1056/NEJMoa044397, 16510744.
19. Berger JR, Houff SA, Major EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. mAbs 2009, 1:1-7.
20. Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis. J Neurol 2009, 256:1771-1772. 10.1007/s00415-009-5200-9, 19609591.
21. Schweikert A, Kremer M, Ringel F, Liebig T, Duyster J, Stuve O, Hemmer B, Berthele A. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009, 66:403-406. 10.1002/ana.21782, 19798640.
22. Hiestand PC, Rausch M, Meier DP, Foster CA. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720. Prog Drug Res 2008, 66:361.
23. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, . FTY720 D2201 Study Group Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355:1124-1140. 10.1056/NEJMoa052643, 16971719.
24. Cohen J, Pelletier J, Kappos L, Barkhof F, Comi G, Hartung HP, Montalban X, Khatri B, Tiel-Wilck K, Izquierdo G. Oral fingolimod (FTY720) significantly reduced relapse rate compared with intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: clinical results from a 12-month phase III study (TRANSFORMS). ECTRIMS 2009,
25. Costello K, Sipe JC. Cladribine tablets' potential in multiple: sclerosis treatment. J Neurosci Nurs 2008, 40:275-280. 10.1097/01376517-200810000-00005, 18856248.
26. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996, 93:1716-1720. 10.1073/pnas.93.4.1716, 40008, 8643695.
27. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann K, Sørensen PS, Vermersch P, Chang P, Hamlett A, Musch B. Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis. ECTRIMS 2009,
28. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000, 54:1726-1733.
29. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M, . LAQ/5062 Study Group Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 371:2085-2092. 10.1016/S0140-6736(08)60918-6, 18572078.
30. Dimitrova P, Skapenko A, Herrmann ML, Schleyerbach R, Kalden JR, Schulze-Koops H. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol 2002, 169:3392-3399.
31. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R, . Teriflunomide Multiple Sclerosis Trial Group and University of British Columbia MS/MRI Research Group A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006, (66):894-900. 10.1212/01.wnl.0000203121.04509.31, 16567708.
32. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN, . BG-12 Phase IIb Study Investigators Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 372:1463-1472. 10.1016/S0140-6736(08)61619-0, 18970976.
33. Gregg C, Shikar V, Larsen P, Mak G, Chojnacki A, Yong VW, Weiss S. White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci 2007, 27:1812-1823. 10.1523/JNEUROSCI.4441-06.2007, 17314279.
34. Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res 2009, 175:239-251. full_text, 2724009, 19660660.
35. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. CAMMS223 Trial Investigators Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801. 10.1056/NEJMoa0802670, 18946064.
36. Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ, Compston DA, Miller DH. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999, 53:751-757.
37. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009, 66:483-489. 10.1001/archneurol.2009.50, 19364933.
38. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007, (69):785-789. 10.1212/01.wnl.0000267662.41734.1f, 17709711.
39. Weber MS, Hemmer B. Cooperation of B Cells and T Cells in the Pathogenesis of Multiple Sclerosis. Results Probl Cell Differ 2009,
40. Racke MK. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol 2008, 21(Supple 1):S9-S18. 10.1097/01.wco.0000313359.61176.15, 18388801.
41. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, . HERMES Trial Group B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688. 10.1056/NEJMoa0706383, 18272891.
42. Stuve O, Leussink VI, Frohlich R, Hemmer B, Hartung HP, Menge T, Kieseier BC. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009, 66:259-261. 10.1001/archneurol.2008.551, 19204165.
43. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008, 65:1443-1448. 10.1001/archneur.65.11.noc80069, 18779415.
44. Benarroch EE. Oligodendrocytes: susceptibility to injury and involvement in neurologic disease. Neurology 2009, (72):1779-1785. 10.1212/WNL.0b013e3181a6b123, 19451534.
45. Yadav V, Marracci G, Lovera J, Woodward W, Bogardus K, Marquardt W, Shinto L, Morris C, Bourdette D. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler 2005, 11:159-165. 10.1191/1352458505ms1143oa, 15794388.
46. Newcombe J, Uddin A, Dove R, Patel B, Turski L, Nishizawa Y, Smith T. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 2008, 18:52-61. 10.1111/j.1750-3639.2007.00101.x, 17924980.
47. Killestein J, Kalkers NF, Polman CH. Glutamate inhibition in MS: the neuroprotective properties of riluzole. J Neurol Sci 2005, 233:113-115. 10.1016/j.jns.2005.03.011, 15949499.
48. Black JA, Waxman SG. Phenytoin protects central axons in experimental autoimmune encephalomyelitis. J Neurol Sci 2008, 274:57-63. 10.1016/j.jns.2008.04.001, 18485368.
49. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005, 233:3-13. 10.1016/j.jns.2005.03.031, 15899499.
50. Kapoor K, Furby J, Hayton T. Outcomes of a phase II randomized controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis. Mult Scler 2009, 15(Suppl 2):27.
51. Mi S, Miller RH, Tang W, Lee X, Hu B, Wu W, Zhang Y, Shields CB, Zhang Y, Miklasz S, Shea D, Mason J, Franklin RJ, Ji B, Shao Z, Chédotal A, Bernard F, Roulois A, Xu J, Jung V, Pepinsky B. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 2009, 65:304-315. 10.1002/ana.21581, 19334062.
52. Loeb JA. Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis. Neurology 2007, 68(Suppl 3):38-54.
53. Azoulay D, Urshansky N, Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol 2008, 195:186-193. 10.1016/j.jneuroim.2008.01.010, 18329726.